ICP-332 Tablets
DrugICP-332 will be administered as tablet
NCT Number: NCT07047612
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.
Interested in participating?
Request Info12 year–75 year
All sexes
Interventional
Phase 2 / Phase 3
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2.
ICP-332 will be administered as tablet
ICP-332 Placebo will be administered as tablet
Time frame: 24 weeks
Time frame: 52 weeks
Contact information is provided by the study sponsor or research team.
Beijing InnoCare Pharma Tech Co., Ltd.
Industry
A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06619184
Non Segmental Vitiligo
Bandung, West Java, Indonesia
View Trial Details